Erratum: Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium (Bioorganic and Medicinal Chemistry Letters (2004) 14 (1811) DOI: 10.1016/j.bmcl.2003.12.103);Preliminary in vitro studies on two potent, water-soluble trimethoprim analogues with exceptional species selectivity against dihydrofolate reductase from Pneumocystis carinii and Mycobacterium avium

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 7, 2004, Pages 1811-1815

  Forsch, Ronald A ^a   Queener, Sherry F ^b   Rosowsky, Andre ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO 5 (5' IODO 3',4' DIMETHOXYBENZYL)PYRIMIDINE; 2,4 DIAMINO 5 [3',4' DIMETHOXY 5' (4 CARBOXYPHENYLETHYNYL)]BENZYLPYRIMIDINE; 2,4 DIAMINO 5 [3',4' DIMETHOXY 5' (5 CARBOXY 1 PENTYNYL)]BENZYLPYRIMIDINE; ANTIINFECTIVE AGENT; DIHYDROFOLATE REDUCTASE; DIHYDROFOLATE REDUCTASE INHIBITOR; ESTER DERIVATIVE; PYRIMIDINE DERIVATIVE; TRIMETHOPRIM; TRIMETHOPRIM DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CALCULATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; IC 50; IN VITRO STUDY; INHIBITION KINETICS; MYCOBACTERIUM AVIUM; NONHUMAN; PNEUMOCYSTIS CARINII; REACTION ANALYSIS; SAPONIFICATION; SOLUBILITY; SONOGASHIRA REACTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TOXOPLASMA GONDII;

MYCOBACTERIUM; MYCOBACTERIUM AVIUM; PNEUMOCYSTIS CARINII; TOXOPLASMA GONDII;

EID: 1542719135     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.03.026     Document Type: Erratum

References (36)

1. Roth B., Falco E.A., Hitchings G.H., Bushby S.R.M. J. Med. Chem. 5:1962;1103.
2. Bushby S.R.M., Hitchings G.H. Br. J. Pharmacol. Chemother. 33:1968;72.
3. Fishman J.A. Antimicrob. Agents Chemother. 42:1998;1309.
4. Kovacs J.A., Gill V.J., Meshnick S., Masur H. JAMA. 286:2001;2450.
5. Kovacs J.A., Hiemenz J.W., Macher A.M., Stover D., Murray H.W., Shelhamer J., Lane H.C., Urmacher C., Honig C., Longo D.L., Parker M.M., Natanson C., Parrillo J.E., Fauci A.S., Pizzo P.A., Masur H. Ann. Intern. Med. 100:1984;663.
6. Henson J.W., Jalaj J.K., Walker R.W., Stover D.E., Fels A.O. Arch. Neurol. 48:1991;406.
7. Oken M.M., Pomeroy C., Weidorf D., Bennett J.M. Am. J. Med. 100:1996;624.
8. Mehta J., Powles R., Singhal S., Riley U., Treleaven J., Catovsky D. Leuk. Lymphoma. 26:1997;83.
9. Torre-Cisneros J., de la Mata M., Lopez-Ciller P., Sanchez-Guijo P., Mino G., Pera C. Transplantation. 62:1996;1519.
10. Baden L.R., Katz J.T., Franck L., Tsang S., Hall M., Rubin R.H., Jarcho J. Transplantation. 75:2003;339.
11. Schweitzer B.I., Dicker A.P., Bertino J.R. FASEB J. 4:1990;2441.
12. Kovacs J.A., Allegra C.J., Beaver J., Boarman D., Lewis M., Parillo J.E., Chabner B., Masur H. J. Infect. Dis. 160:1989;312.
13. Medina I., Mills J., Leoung G., Hopewell P.C., Lee B., Modin G., Benowitz W.C.B. N. Engl. J. Med. 323:1990;776.
14. Bayard P.J., Berger T.G., Jacobson M.A. J. Acquir. Immune Def. Syndr. 5:1992;1237.
15. Allegra C.J., Chabner B.A., Tuazon C.U., Ogata-Arakaki D., Baird B., Drake J.C., Simmons J.T., Lack E.E., Shelhamer J.H., Balis F., Walker W., Kovacs J.A., Lane H.C., Masur H. N. Eng. J. Med. 317:1987;978.
16. Sattler F.R., Frame P., Davis R., Nichols L., Shelton B., Akil B., Baughman R., Hughlett C., Weiss W., Boylen C.T., van der Horst C., Black J., Powderly W., Steigbigel R.T., Leedom J.M., Masur H., Feinberg J., Benoit S., Eyster E., Gocke D., Beck K., Lederman M., Phari J., Reichman R., Sacks H.S., Soiero R. J. Infect. Dis. 170:1994;165.
17. Kovacs J.A., Allegra C.J., Swan J.C., Drake J.C., Parrillo J.E., Chabner B.A., Masur H. Antimicrob. Agents Chemother. 32:1988;430.
18. Falloon J., Allegra C.A.J., Kovacs J., O'Neill D., Ogata-Arakaki D., Feuerstein I., Polis M., Davey R., Lane H.C., LaFon S., Rogers M., Zunich K., Turlo J., Tuazon D., Parenti D., Simon G., Mazur H. Clin. Res. 38:1990;361A.
19. Rosowsky A., Forsch R.A., Queener S.F. J. Med. Chem. 45:2002;233.
20. Rosowsky A., Forsch R.A., Queener S.F. J. Med. Chem. 46:2003;1726. This paper may be consulted for a comprehensive bibliography of our past work on DHFR inhibitors as potential drugs against opportunistic infections.
21. Rosowsky, A.; Forsch, R. A.; Sibley, C. H.; Inderlied, C. B.; Queener, S. F. Manuscript submitted.
22. Kuyper L.F., Roth B., Baccanari D.P., Ferone R., Beddell C.R., Champnesss J.N., Stammers D.K., Dann J.G., Norrington F.E., Baker D.J., Goodford P.J. J. Med. Chem. 28:1985;303.
23. Calas M., Barbier A., Giral L., Balmayer B., Despaux E. Eur. J. Med. Chem. 17:1982;497.
24. Stuart A., Paterson T., Roth B., Aig E. J. Med. Chem. 26:1983;667.
25. Sonogashira K., Tohda Y., Hagihara B. Tetrahedron Lett. 1975;4467.
26. Rosowsky A., Cody V., Galitsky N., Fu H., Papoulis A., Queener S.F. J. Med. Chem. 42:1999;4853.
27. Kompis, I.; Blaney, J. M.; Marlow, C. K. International Patent WO 92/ 08461 (29 May 1992), assigned to Protos Corporation, Emeryville, CA.
28. Braunsteiner A.R., Finsinger F. J. Chemother. 5:1993;507.
29. Braga P.C., Dal Sasso M., Maci S., Bondiolotti G., Fonti E., Reggio S. Antimicrob. Agents Chemother. 40:1996;2392.
30. 22 However, only the synthesis of this compound was described in the patent, and no data on binding to either Pc or Ma were disclosed.
31. Guerry, P.; Jolidon, S.; Masciadri, R.; Salder, H.; Then, R. U.S. Patent 5,763,450 (9 June 1998), assigned to Hoffmann-La Roche, Inc., Nutley, NJ.
32. Chen F., Cushion M.T. J. Clin. Microbiol. 32:1994;2791.
33. Cushion M.T., Chen F., Kloepfer N. Antimicrob. Agents Chemother. 41:1997;379.
34. We are grateful to Dr. Melanie Cushion, Dept. of the VA Medical Center, University of Cincinnati, for kindly performing these assays.
35. 13.
36. 14 reported that 2,4-diamino-5-[3′,4′-dimethoxy-5′-(5- carboxypentyloxy)]pyrimidine, a structural analogue of 6, had nearly the same activity as TMP against S. aureus, but was 300-fold less active than TMP against E. coli organisms in culture even though it had 50-fold greater affinity for E. coli DHFR in a cell-free assay.